PATENT CLAIM ANALYSIS

Application Number: 16211757
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-03
Patent Classification: ["514", "012000"]

Abstract:
The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Claim (Index 9):
The method of  claim 7  wherein the amount of ADNS peptide sufficient to reduce apoptosis is determined by detecting an increase in GAPDH localization in the cytosol or membrane after the cells are contacted with the peptide.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 98.0
- Lexical Diversity: 1.2093
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14153844', '13586617', '08182183', '11572397', '13855533']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8026904451191464
- 35 USC 102 Novelty (BERT): 0.6088670998141168
- Combined Prediction Score: 0.7833081105886435
- Mean Citation Score: 458.1035599999999
- Max Citation Score: 643.7299
- Similarity Product: 436.121871903956

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test